Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.

PHASE1/PHASE2Enrolling by invitationINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 4, 2024

Primary Completion Date

March 9, 2026

Study Completion Date

August 31, 2026

Conditions

Chronic Lymphocytic Leukaemia (CLL)Small Lymphocytic Lymphoma (SLL)

Interventions

DRUG

Lenalidomide

Dose Level 1

DRUG

Lenalidomide

Dose Level 2

Trial Locations (1)

Hematology/Oncology department, Vitebsk

All Listed Sponsors

collaborator

Republican Scientific and Practical Center for children's Oncology, Hematology and Immunology

UNKNOWN

lead

Vitebsk Regional Clinical Cancer Centre

OTHER